
Avastin/Lucentis controversy continues
"Why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?? so asked Irv Arons in his blog spot.
“As I read the news release from the NEI/NIH yesterday morning, about the one-year results of the clinical trial evaluating the combination use of Lucentis with pan-retinal laser therapy to treat diabetic macular oedema, prior to posting it online, and later, when I read the complete study as posted in Ophthalmology, the one thought that kept running through my mind was, why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?” so said Irv Arons in his blog spot.
What do you think? Tell us at
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
















































